Crinetics Pharmaceuticals (CRNX) Deferred Taxes (2017 - 2018)
Crinetics Pharmaceuticals (CRNX) posted quarterly Deferred Taxes of -$374000.0 for Q4 2018, down 12566.67% year-over-year from N/an in Q4 2017, and down 1110.81% quarter-over-quarter from $37000.0 in Q3 2018.
Powered by 
Analysis
Crinetics Pharmaceuticals (CRNX) Deferred Taxes (2017 - 2018) Analysis & Trends
Crinetics Pharmaceuticals' Deferred Taxes history runs 2 years deep, the most recent figure standing at -$374000.0 for Q4 2018.
- In Q4 2018, Deferred Taxes fell 12566.67% year-over-year to -$374000.0; the TTM figure through Dec 2018 stood at -$332000.0 (changed N/A YoY), while the FY2018 annual figure was -$261000.0, down 1840.0% from the prior year.
- Deferred Taxes for Q4 2018 stood at -$374000.0, down from $37000.0 in the prior quarter.
- The five-year high for Deferred Taxes was $37000.0 in Q3 2018, with the low at -$374000.0 in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 2.66 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 10 | Crinetics Pharmaceuticals | 8.99 Bn | 8.99 Bn | 24.96 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | -374,000.00 |
| Sep 30, 2018 | 37,000.00 |
| Dec 31, 2017 | 3,000.00 |
| Sep 30, 2017 | 2,000.00 |